STEERLife is a unique and seamless blend of engineering and pharmaceutical sciences - one that is committed to the design and development of solutions that can transform the way we make and take medicines.
REVOLUTIONISING THE BATCH TO CONTINUOUS (B2C) PARADIGM
STEERLife's technology solutions help manufacturers transition from batch to true continuous processing, with ease. They offer greater control over process and product by enabling ‘Quality by Design’. Besides, these custom-built solutions are scalable, versatile and time & cost efficient.
OUR DELIVERY SYSTEMS
We also work with manufacturers to develop new drug delivery systems and differentiated products. For instance, our patented Effervescence Technology (EVT) is changing the way people take medicines by enabling a move from swallowing to sipping. Our expertise in application technologies has also led to the development of solutions for enhanced bio- availability / solubility, containment, drug abuse deterrence, extended release and taste-masking.
IT'S TIME TO CHANGE!
At STEERLife, we are driven by innovation. We are committed to collaborating with our partners in providing solutions that can help the industry break-free from regulatory burden and inefficiency. We believe that it is time to look at transformational new ways of manufacturing and delivering medicines. We believe that it is time to change!
STEERLife— A STEER GROUP COMPANY
STEERLife is a part of the STEER Group. Founded in 1993 by Dr. Babu Padmanabhan, the STEER Group is committed to the design, creation and implementation of advanced materials platform technologies that effectively transform and functionalise materials in the field of pharmaceuticals, plastics, food & nutraceuticals, biomaterials and biorefining. Operating 5 global offices, 10 satellite offices, 3 Application Development Centers and supported by a talented workforce of over 500 engineers, scientists and technicians, the STEER Group serves over 39 countries across the globe. STEER is driven by innovation and holds 11 patents along with 25 others that have been applied for. With a vision to ‘STEER A NEW WORLD’, the group remains focused on the development of advanced platform technologies and processes to improve the quality of life and change the way people live, eat and stay healthy.
A pharmacy graduate from BHU and a postgraduate from UK, Dr. Sen spent 11 years with Bristol-Myers Squibb in the UK in areas of pharmaceutical development, technology transfer, plant support, drug delivery systems and generic product development. Since his return to India in 1990, he has spent over 2 decades with leading Indian pharmaceutical companies, namely Ranbaxy and Lupin Limited. In these leadership positions, he is credited with driving the generic revolution from India. During an extensive career spanning more than 3 decades, Dr. Sen has been responsible for the development and approval of more than a 100 regulatory submissions and approvals for the US and EU markets namely in ANDAs, NDAs, INDs and NDDS. He has more than 50 patents to his name, a majority of which are commercially available products in global markets and has also been responsible for licensing a drug delivery technology-based product to an MNC.
Dr. Babu's journey began with a vision — to steer a new world. He has made significant contributions to the field of polymer processing. His work in designing processing section components has led to the development of intelligent compounding technology that has redefined pharmaceutical manufacturing. The fractional lobed processor (FLP) invented by him provides critical break-through in continuous granulation.
MD & CHIEF KNOWLEDGE OFFICER
CHAIRMAN - STEER AMERICA
Mr. Dipak Chattaraj is the Ex-Chairman, Ranbaxy Pharmaceuticals Inc., U.S., and Ex-President (Corporate Development and Strategy), Ranbaxy Laboratories Ltd.
He retired from Ranbaxy in 2011 and now consults for the pharmaceutical industry in India as well as the United States. Dipak leads STEER America as Chairman.
Mr.Indu Bhushan, brings more than 2 decades of core pharmaceutical development experience to the table. With his contribution to more than 20 publications and patents, his current research activities in STEERLife focus on creating a difference to the way pharmaceuticals are manufactured and administered. Prior to STEERLife, he was associated with several leading multinational companies where he played a key role in setting up the facilities and resources for the development of generic and specialty pharmaceuticals.